Product
Perjeta + Trastuzumab + Carboplatin + Docetaxel
1 clinical trial
1 indication
Clinical trial
A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients With Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Stage or Locally Advanced Breast CancerStatus: Not yet recruiting, Estimated PCD: 2026-03-15